Literature DB >> 17851050

Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.

Marie-Francoise Tripodi1, Emanuele Durante-Mangoni, Rosaria Fortunato, Riccardo Utili, Raffaele Zarrilli.   

Abstract

This study evaluated the activity of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against nine epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemase in Naples, Italy. The isolates were susceptible to colistin but differed in their resistance to imipenem and rifampicin. Time-kill studies showed a bactericidal effect for colistin but not for imipenem, rifampicin or sulbactam/ampicillin used as single agents. Synergism was observed with combinations of rifampicin+imipenem or sulbactam/ampicillin for all isolates and with colistin+rifampicin for isolates showing higher minimum inhibitory concentrations for rifampicin. Combined use of the antimicrobials tested may provide good therapeutic options for OXA-58 carbapenemase-producing A. baumannii infections.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17851050     DOI： 10.1016/j.ijantimicag.2007.07.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  25 in total

1.  Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii.

Authors:  N C Gordon; K Png; D W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

2.  Molecular Epidemiology and Mechanism of Sulbactam Resistance in Acinetobacter baumannii Isolates with Diverse Genetic Backgrounds in China.

Authors:  Yunxing Yang; Ying Fu; Peng Lan; Qingye Xu; Yan Jiang; Yan Chen; Zhi Ruan; Shujuan Ji; Xiaoting Hua; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria.

Authors:  Kwang-sun Kim; Taeyeon Kim; Jae-Gu Pan
Journal:  J Antibiot (Tokyo)       Date:  2015-01-14       Impact factor: 2.649

Review 4.  Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Authors:  Phillip J Bergen; Zackery P Bulman; Sarith Saju; Juergen B Bulitta; Cornelia Landersdorfer; Alan Forrest; Jian Li; Roger L Nation; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2015-01       Impact factor: 4.705

Review 5.  Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.

Authors:  P Poulikakos; G S Tansarli; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-16       Impact factor: 3.267

6.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

7.  In vitro activity of antibiotic combinations against multidrug-resistant strains of Acinetobacter baumannii and the effects of their antibiotic resistance determinants.

Authors:  Yoko Miyasaki; Margie A Morgan; Raymond C Chan; W Stephen Nichols; Kristine M Hujer; Robert A Bonomo; A Rekha Murthy
Journal:  FEMS Microbiol Lett       Date:  2012-01-06       Impact factor: 2.742

8.  In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.

Authors:  Martha Nepka; Efstathia Perivolioti; Eleni Kraniotaki; Lida Politi; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

10.  Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Hee Ji Lee; Phillip J Bergen; Jurgen B Bulitta; Brian Tsuji; Alan Forrest; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.